Elevation of plasma homocysteine and minor hallucinations in Parkinsons disease: a cross-sectional study
Key Metabolic Challenges: Chronic stress, poor diet, and toxins disrupt gut microbiome, leading to inflammation and metabolic dysfunction
Despite these mechanistic differences, both drug classes consistently outperform many other therapeutic options in reducing anthropometric parameters such as body weight and body mass index
Medicaid coverage is determined by individual states, so while some states have begun covering GLP-1s for obesity treatment, others continue to limit their use to diabetes management
Multiple groups have studied, characterised, and observed both compounds across in vitro, animal-model, and clinical-research contexts the combined-compound translation is not yet documented in clinical-trial-stage publications